Ketamine Hydrochloride Injection, USP — 100 mg/mL
Original price was: $150.00.$145.88Current price is: $145.88.
Ketamine Hydrochloride Injection, USP — 100 mg/mL
Description
Ketamine Hydrochloride Injection, USP — 100 mg/mL
Catalog #: [SKU] · Presentation: 10 mL multiple-dose vial · Schedule: CIII (US DEA)
Availability: Restricted — licensed veterinary practitioners and registered research institutions only
Product Description
Ketamine Hydrochloride Injection, USP is a sterile, non-pyrogenic aqueous solution of ketamine hydrochloride
intended for intravenous or intramuscular administration. Ketamine is a rapid-acting dissociative anesthetic
agent that produces a state of profound analgesia, normal pharyngeal-laryngeal reflexes, normal or slightly
enhanced skeletal muscle tone, cardiovascular and respiratory stimulation, and occasionally transient and
minimal respiratory depression.
Each mL contains ketamine hydrochloride equivalent to 100 mg ketamine base, [preservative, e.g. benzethonium
chloride 0.01%] as preservative, and Water for Injection q.s. pH adjusted with hydrochloric acid as required
(pH range 3.5–5.5). Solution is clear and colorless; do not use if discolored or if particulate matter is present.
Supplied for use in veterinary medicine and for in vitro / non-clinical laboratory research under an appropriate
controlled-substance registration. Not for human use. Not for resale to end consumers.
Key Specifications
| Attribute | Specification |
|---|---|
| Active ingredient | Ketamine hydrochloride |
| Concentration | 100 mg/mL (ketamine base equivalent) |
| CAS number | 1867-66-9 (HCl salt) |
| Molecular formula | C₁₃H₁₆ClNO · HCl |
| Molecular weight | 274.19 g/mol |
| Dosage form | Sterile solution for injection (IV/IM) |
| Fill volume | 10 mL |
| Container | Type I amber glass vial, elastomeric stopper, flip-off aluminum seal |
| Purity / assay | 98.0–102.0% of labeled amount (USP) |
| Sterility | Meets USP <71> |
| Endotoxin | Meets USP <85> |
| Grade | USP / Ph. Eur. compliant |
| Storage | 20–25 °C (68–77 °F); excursions 15–30 °C permitted. Protect from light. Do not freeze. |
| Shelf life | 24 months from date of manufacture (unopened) |
| In-use stability | Discard multiple-dose vial within 28 days of first puncture |
Product Highlights
- Rapid onset, short duration — anesthetic effect typically within 30–60 seconds IV; recovery is dose-dependent and generally rapid.
- Preserved cardiovascular stability — sympathomimetic activity supports heart rate and blood pressure, useful in compromised patients.
- Versatile route options — validated for both intravenous and intramuscular administration.
- Combination-friendly — commonly co-administered with alpha-2 agonists, benzodiazepines, or opioids as part of balanced anesthesia protocols.
- Consistent quality — manufactured under cGMP; each lot released against USP monograph specifications with a Certificate of Analysis.
- Full documentation package — CoA, SDS, and lot traceability supplied with every shipment.
Indicated Uses (Veterinary)
Approved species and indications vary by market authorization. Where labeled, ketamine is indicated for:
- Restraint and short-duration procedural anesthesia in cats and subhuman primates.
- Induction of anesthesia prior to inhalant maintenance, as part of a balanced protocol.
- Diagnostic and minor surgical procedures not requiring skeletal muscle relaxation.
Refer to the approved package insert for your jurisdiction for species-specific dosing. Dosing decisions are
the responsibility of the attending licensed veterinarian.
Warnings and Precautions
- Controlled substance. Ketamine is a Schedule III controlled substance in the United States and is
scheduled or otherwise restricted in most jurisdictions. Diversion, misuse, and abuse carry legal penalties. - Secure storage required. Store in a securely locked, substantially constructed cabinet with access limited
to authorized personnel. Maintain perpetual inventory and dispensing records per DEA 21 CFR Part 1304 or
local equivalent. - Ketamine does not produce adequate skeletal muscle relaxation; supplemental agents may be required.
- Emergence reactions (vocalization, ataxia, excitement) may occur during recovery; recover animals in a quiet,
dimly lit environment. - Use with caution in patients with elevated intracranial or intraocular pressure, significant hypertension,
cardiac decompensation, or hepatic/renal impairment. - Airway management equipment, oxygen, and resuscitation capability must be immediately available.
- Not for use in animals intended for human consumption unless specifically permitted by local authority;
observe applicable withdrawal periods. - Handle with standard PPE. Avoid accidental self-injection — seek immediate medical attention if it occurs.







Reviews
There are no reviews yet.